Development of an IgG-Fc fusion COVID-19 subunit vaccine, AKS-452.

Vaccine · 2021 · PMC8491978 · PMID 34642088

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

extremely significantno p-value reported

This manufacturing capacity is extremely significant and far superior to the production throughput and costs of the other viral-based, nucleic acid-based, and full-length recombinant SP subunit-based vaccines.

also in 7,787 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.